Vanguard Global Advisers
INMB icon

Vanguard Global Advisers’s INmune Bio INMB Stock Holding History

Vanguard Global Advisers’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,539
Closed -$5.13K – 3690
2026
Q1 		$5.13K Buy
+4,539
New +$6.47K ﹤0.01% 3555

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Vanguard Global Advisers's INMB Position: Q2 2026 in Review

Vanguard Global Advisers sold out of INmune Bio (INMB) in Q2 2026, closing a stake of 4,539 shares — an estimated $5.13K sold.

Vanguard Global Advisers first reported a position in INMB in Q1 2026 and held it in 1 quarter. The position peaked at $5.13K in Q1 2026. 79 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Vanguard Global Advisers reported no remaining INmune Bio position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 4,539 INmune Bio shares in Q2 2026, an estimated $5.13K.
  • Vanguard Global Advisers first reported a position in INmune Bio in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's INmune Bio position peaked at $5.13K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.